Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Long-Term Investments (2016 - 2024)

Historic Long-Term Investments for Seres Therapeutics (MCRB) over the last 9 years, with Q1 2024 value amounting to $1.4 million.

  • Seres Therapeutics' Long-Term Investments changed 0.0% to $1.4 million in Q1 2024 from the same period last year, while for Mar 2024 it was $1.4 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $1.4 million for FY2023, which is 0.0% changed from last year.
  • Seres Therapeutics' Long-Term Investments amounted to $1.4 million in Q1 2024, which was down 0.0% from $1.4 million recorded in Q4 2023.
  • In the past 5 years, Seres Therapeutics' Long-Term Investments ranged from a high of $49.8 million in Q4 2020 and a low of $1.4 million during Q1 2020
  • For the 5-year period, Seres Therapeutics' Long-Term Investments averaged around $8.2 million, with its median value being $1.4 million (2021).
  • In the last 5 years, Seres Therapeutics' Long-Term Investments skyrocketed by 345892.86% in 2020 and then plummeted by 9718.82% in 2021.
  • Over the past 5 years, Seres Therapeutics' Long-Term Investments (Quarter) stood at $49.8 million in 2020, then plummeted by 97.19% to $1.4 million in 2021, then changed by 0.0% to $1.4 million in 2022, then changed by 0.0% to $1.4 million in 2023, then changed by 0.0% to $1.4 million in 2024.
  • Its Long-Term Investments stands at $1.4 million for Q1 2024, versus $1.4 million for Q4 2023 and $1.4 million for Q3 2023.